Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy

Archives of Otolaryngology - Head and Neck Surgery

Volumn 132, Issue 2, 2006, Pages 141-145

  Ozsahin, Mahmut ^a   Betz, Michael ^a   Matzinger, Oscar ^a   Bron, Luc ^a   Luthi, François ^a   Pasche, Philippe ^a   Azria, David ^a   Mirimanoff, René O ^a   Zouhair, Abderrahim ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; DOLASETRON MESILATE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; FIBROSIS; HEAD AND NECK CANCER; HUMAN; HYPOTENSION; MALE; MUCOSA INFLAMMATION; NAUSEA; POSTOPERATIVE PERIOD; RADIATION DOSE; RETROSPECTIVE STUDY; SKIN MANIFESTATION; TREATMENT REFUSAL; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33644830789     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archotol.132.2.141     Document Type: Article

References (35)

1. Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol. 2003;4:529-536.
2. Stephens LC, Schultheiss TE, Price RE, et al. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer. 1991;67:1539-1543.
3. Moller P, Perrier M, Ozsahin M, Monnier P. A prospective study of salivary gland function in patients undergoing radiotherapy for squamous cell carcinoma of the oropharynx. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97:173-189.
4. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials. Int J Hematol. 2000;72:425-435.
5. Buntzel J, Glatzel M, Kuttner K, et al. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol. 2002;12(1, suppl 1):4-13.
6. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
7. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol. 2000;18:2226-2233.
8. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004;58:1369-1377.
9. Anné PR, Curran WJ Jr. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. Semin Radiat Oncol. 2002;12(1, suppl 1):18-19.
10. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer. 1992;69:2820-2825.
11. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissue by S-2-(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res. 1980;40:1519-1524.
12. International Union Against Cancer (UICC). In: Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002: 19-47.
13. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
14. Zouhair A, Azria D, Pasche P, et al. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. Radiother Oncol. 2004;70:183-188.
15. Kutter J, Ozsahin M, Monnier P, Stupp R. Combined modality treatment with full dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. Eur Arch Otorhinolaryngol. 2005;262:1-7.
16. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Piquet MA, Ozsahin M, Larpin I, et al. Early nutritional intervention in oropharyngeal cancer patients undergoing radiotherapy. Support Care Cancer. 2002;10:502-504.
20. Taylor SE, Miller EG. Preemptive pharmacologic intervention in radiation-induced salivary dysfunction. Proc Soc Exp Biol Med. 1999;221:14-26.
21. Epstein JB, Robertson M, Emerton S, et al. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001;23:389-398.
22. Maes A, Weltens C, Flamen P, et al. Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol. 2002;63:203-211.
23. Fogliata A, Cozzi L, Bieri S, Bernier J. Critical appraisal of a conformal head and neck cancer irradiation avoiding electron beams and field matching. Int J Radiat Oncol Biol Phys. 1999;45:1331-1338.
24. Lee N, Akazawa C, Akazawa P, et al. A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:584-594.
25. Cozzi L, Fogliata A, Bolsi A, Nicolini G, Bernier J. Three-dimensional conformal vs intensity-modulated radiotherapy in head-and-neck cancer patients: comparative analysis of dosimetric and technical parameters. Int J Radiat Oncol Biol Phys. 2004;58:617-624.
26. Chao KS, Ozyigit G, Thorsdad WL. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine. Semin Oncol. 2003;30(6, suppl 18):101-118.
27. Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys. 2004;59:242-249.
28. Schuchter LM. Guidelines for the administration of amifostine. Semin Oncol. 1996;23(4, suppl 8):40-43.
29. Koukourakis MI. Amifostine: is there evidence of tumor protection? Semin Oncol. 2003;30(6, suppl 18):18-30.
30. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;52:739-747.
31. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-2903.
32. Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol. 2003; 30(6, suppl 18):31-39.
33. Thorstad WL, Chao KSC, Haughey B. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. Semin Oncol. 2004;31(6, suppl 18):8-12.
34. Rosenthal DI, Chambers MS, Weber RS, Eisbruch A. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Semin Oncol. 2004;31(6, suppl 18):25-28.
35. McDonald S, Meyerowitz C, Smudzin T, Rubin P. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys. 1994;29:747-754.